Recruiting
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
ClinicalTrials.gov IDNCT06274801
PhasePHASE3
Enrollment330
SponsorGossamer Bio USA, Inc.
Age18 Years – 75 Years
SexALL
Conditions studied
Pulmonary Arterial Hypertension
About this study
This open-label extension study will evaluate the long-term safety, tolerability and efficacy of orally inhaled seralutinib in subjects who have completed a previous seralutinib study
Interventions
- Drug: Seralutinib — Capsule containing seralutinib
- Device: Gereic Dry Powder Inhaler — Generic dry powder inhaler for seralutinib delivery
Primary outcomes
- Incidence of treatment-emergent adverse events (TEAEs) (From baseline to end of study (up to 48 months or availability of commercial product))
Eligibility information
Inclusion Criteria:
1. Subjects must have completed a qualifying last visit in a prior seralutinib PAH study on investigational product (IP) and in accordance with the protocol.
2. Evidence of an informed consent document, signed and dated by the subject, indicating that the subject has been informed of all pertinent aspects of the study prior to initiation of any subject-mandated procedures.
3. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
4. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test at enrollment visit before first administration of Investigational Product (IP) in this study.
5. WOCBP who are not abstinent and intend to be sexually active with a non-sterilized male partner must be willing to use a highly effective method of contraception from consent through 30 days following the last administration of IP.
6. Male subjects: Non-sterilized male subjects who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom from consent through 90 days after the last dose of IP.
Exclusion Criteria:
1. Severe acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation or seralutinib administration, unless associated with an ongoing AE and discussed with the Sponsor's medical monitor (MM) (or designee).
2. Have any other condition or reason that, in the opinion of the Investigator, would prohibit the subject from participating in the study.
Study locations
- Valley Advanced Lung Diseases Institute, Fresno, California 93720 United States
- Department of Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California 90073 United States
- UC Davis Health Medical Center, Sacramento, California 95817 United States
- Stanford Healthcare, Stanford, California 94305 United States
- University of Florida Health, Gainesville, Florida 32610 United States
- Mayo Clinic Jacksonville, Jacksonville, Florida 32224 United States
- Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead, Atlanta, Georgia 30309 United States
- The Emory Clinic, Atlanta, Georgia 30322 United States
- Northside Hospital - Atlanta, Atlanta, Georgia 30342 United States
- UI Health Hospital, Chicago, Illinois 60612 United States
Showing 10 of 120 reported sites. See the official listing for all locations.
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-11-18.